 |
 |
|
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Summaries for Patients are a service provided by Annals to help patients better understand the complicated and often mystifying language of modern medicine.
Most often, people get HCV from sharing contaminated needles with persons who are already infected. The virus is particularly common in inmates, primarily because many inmates have histories of drug abuse. Each year, nearly one third of all Americans who are infected with the virus are in prison. Most inmates do not get treated, even though some are in prison for prolonged periods. In fact, evidence on treatment of inmates with HCV infection is sparse.
SUMMARIES FOR PATIENTS
Treatment for Hepatitis C Virus Infection among Inmates
4 February 2003 | Volume 138 Issue 3 | Page I-50
Summaries for Patients are presented for informational purposes only. These summaries are not a substitute for advice from your own medical provider. If you have questions about this material, or need medical advice about your own health or situation, please contact your physician. The summaries may be reproduced for not-for-profit educational purposes only. Any other uses must be approved by the American College of Physicians-American Society of Internal Medicine.
The summary below is from the full report titled "Treatment of Chronic Hepatitis C in a State Correctional Facility." It is in the 4 February 2003 issue of Annals of Internal Medicine (volume 138, pages 187-190). The authors are SA Allen, AC Spaulding, AM Osei, LE Taylor, AM Cabral, and JD Rich.
What is the problem and what is known about it so far?
Hepatitis C virus (HCV) is the most common bloodborne virus in the United States. In some people, it can cause chronic hepatitis (persistent inflammation of the liver), cirrhosis (permanent scarring of the liver), and liver failure. Chronic HCV infection also increases risk for liver cancer. Strong antiviral drugs given for long periods (6 to 12 months) can make HCV disappear. These drugs are difficult to take and have many side effects. Doctors usually won't give them to people who drink too much, "shoot up" drugs, have severe liver disease or other serious medical problems, are pregnant or unwilling to practice contraception, or have severe psychiatric problems.
Why did the researchers do this particular study?
To describe treatment and outcomes of chronic HCV infection in individuals who are in prison for a prolonged period.
Who was studied?
93 HCV-infected inmates with sentences of 15 months or greater.
How was the study done?
The researchers reviewed medical records of inmates who had been housed at correctional facilities in the Rhode Island Department of Corrections between 1997 and 2001. During this time, six doctors identified 93 individuals with chronic HCV infection and prolonged sentences. Three of the individuals were not given treatment because of unstable psychiatric disease. The researchers describe the treatment course and outcomes of the remaining 90 HCV-infected inmates who were treated with antiviral therapy.
What did the researchers find?
Ten inmates discontinued treatment within 6 months because of side effects. One died of liver failure. Fifty of the 79 inmates who received antiviral therapy for at least 6 months had no evidence of virus in their blood at 6 months. Thirty-four had blood tests for the virus 6 months after completing therapy. Of these inmates, 26 had no evidence of virus.
What were the limitations of the study?
The study took place in correctional facilities in one state, Rhode Island. We do not know whether inmates of other correctional facilities receive similar treatment or have similar outcomes.
What are the implications of the study?
Antiviral therapy for chronic HCV infection may be feasible in correctional settings, particularly for those inmates with addiction or mental illness, but costs and long-term clinical outcomes are unknown.
Related articles in Annals:
This article has been cited by other articles:
|
|
 |
|
  T. Lincoln, R. W. Tuthill, S. L. DePietro, M. J. Tocco, K. Keough, and T. J. Conklin Viral Hepatitis, Risk Behaviors, Aminotransferase Levels, and Screening Options at a County Correctional Center Journal of Correctional Health Care, October 1, 2006; 12(4): 249 - 261. [Abstract] [PDF]
|
|
|
|
 |
|
 C. C. Crone, G. M. Gabriel, and A. DiMartini An Overview of Psychiatric Issues in Liver Disease for the Consultation-Liaison Psychiatrist Psychosomatics, June 1, 2006; 47(3): 188 - 205. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 T. M. Hammett HIV/AIDS and Other Infectious Diseases Among Correctional Inmates: Transmission, Burden, and an Appropriate Response Am J Public Health, June 1, 2006; 96(6): 974 - 978. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. C. Spaulding, C. M. Weinbaum, D. T.-Y. Lau, R. Sterling, L. B. Seeff, H. S. Margolis, and J. H. Hoofnagle A Framework for Management of Hepatitis C in Prisons Ann Intern Med, May 16, 2006; 144(10): 762 - 769. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. Farley, S. Vasdev, B. Fischer, E. Haydon, J. Rehm, and T. A. Farley Feasibility and Outcome of HCV Treatment in a Canadian Federal Prison Population Am J Public Health, October 1, 2005; 95(10): 1737 - 1739. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
C. E. Munoz-Plaza, S. M. Strauss, J. M. Astone, D. C. Des Jarlais, and H. Hagan Hepatitis C Service Delivery in Prisons: Peer Education From the "Guys in Blue" Journal of Correctional Health Care, July 1, 2005; 11(4): 347 - 368. [Abstract] [PDF]
|
|
|
|
 |
|
 M. A. Rifai and D. L. Rosenstein Hepatitis C and Psychiatry Focus, April 1, 2005; 3(2): 194 - 202. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. Paris, M. M. Pradhan, S. Allen, and W. M. Cassidy Cost of Hepatitis C Treatment in the Correctional Setting Journal of Correctional Health Care, April 1, 2005; 11(2): 199 - 212. [Abstract] [PDF]
|
|
|
|
|
|
D. Bernstein Treatment of Chronic Hepatitis C in a State Correctional Facility Ann Intern Med, January 20, 2004; 140(2): 150 - 151. [Full Text] [PDF]
|
|
|
|
|
|
Correction: Treatment of Chronic Hepatitis C in a State Correctional Facility Ann Intern Med, October 7, 2003; 139(7): 605 - 605. [Full Text] [PDF]
|
|
|
|
|
|
T. M. Hammett Adopting More Systematic Approaches to Hepatitis C Treatment in Correctional Facilities Ann Intern Med, February 4, 2003; 138(3): 235 - 236. [Full Text] [PDF]
|
|
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Article
